Kopra Bio
Genetically engineered viruses that teach your immune system to kill…
Based based in San Francisco, CA, USA, Kopra Bio works in healthcare.
Profile
Kopra Bio makes genetically engineered viruses that teach your immune system to kill cancer using tech we developed at UCSF. We’re making the next Keytruda ($25B/yr cancer drug blockbuster) starting with the most aggressive form of brain cancer, glioblastoma. In the most challenging brain cancer model, we improve survival from 0% with the current FDA approved treatment to 90% with our treatment.
Within the healthcare space, the company focuses on its core offering rather than a broad product line.
San Francisco, CA, USA is where the company is located.
It is recorded at the Summer 2024 stage.
Recorded headcount: 2 employees.
Directory analysis
Kopra Bio is a San Francisco‑based biotech that develops genetically engineered viruses designed to train the immune system to kill cancer cells, with an initial focus on glioblastoma. The company claims preclinical data showing a dramatic increase in survival rates compared to current FDA‑approved treatments.
Positioning: Positioned within the emerging viral immunotherapy niche of oncology, Kopra Bio is an early‑stage startup with limited personnel and undisclosed funding, implying significant scientific and regulatory challenges ahead.
Note: Kopra Bio is a small biotech working on viral immunotherapy for aggressive cancers.
Auto-generated directory analysis from public data · updated 11 Oct 2026. Informational only, not investment advice.
| Sector | Healthcare |
|---|---|
| Headquarters | San Francisco, CA, USA |
| Country | USA |
| Employees | 2 |
| Stage | Summer 2024 |
Website: kopra.bio
Browse related
Create a free account